Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Post-Traumatic Stress Disorder (PTSD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline landscape.
Post-traumatic stress disorder (PTSD) is a mental health condition that's triggered by a terrifying event either experiencing it or witnessing it. Symptoms include flashbacks, nightmares and severe anxiety, as well as uncontrollable thoughts about the event. Treatment includes antidepressants, anti-anxiety and cognitive therapy.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Post-Traumatic Stress Disorder (PTSD) - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Post-Traumatic Stress Disorder (PTSD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 10, 13, 47, 13 and 1 respectively. Similarly, the Universities portfolio in Phase III, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively.
Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System)
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Post-Traumatic Stress Disorder (PTSD) (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Post-Traumatic Stress Disorder (PTSD) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post-Traumatic Stress Disorder (PTSD) - Overview
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Post-Traumatic Stress Disorder (PTSD) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Post-Traumatic Stress Disorder (PTSD) - Companies Involved in Therapeutics Development
Post-Traumatic Stress Disorder (PTSD) - Drug Profiles
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products
Post-Traumatic Stress Disorder (PTSD) - Product Development Milestones
Featured News & Press Releases
Mar 08, 2022: Apex Labs granted phase 2a clinical trial application approval by Health Canada for treatment of PTSD in veterans
Feb 28, 2022: Creso Pharma’s wholly-owned psychedelics subsidiary, Halucenex Life Sciences secures Clinical Trial Authorisation for its phase II clinical trial with Health Canada
Feb 03, 2022: Lactocore Group findings show promise in treating anxiety and depression
Jan 25, 2022: Creso Pharma’s wholly-owned psychedelics subsidiary, Halucenex Life Sciences lodges clinical trial authorisation for phase II clinical trial with Health Canada
Jan 24, 2022: Mydecine Partners with Combat Stress to treat post-traumatic stress disorder in veterans
Jan 19, 2022: Numinus announces key milestones in MAPS-sponsored MDMA-assisted therapy for PTSD clinical trial
Jan 19, 2022: Neurovation Labs announces issuance of U.S. patent covering composition and methods for detecting PTSD in living subjects
Jan 10, 2022: Mydecine achieves innovative supercomputing artificial intelligence modeling in psychedelic drug development enabling quick screening of billions of compounds
Dec 30, 2021: Jazz Pharmaceuticals announces first patient enrolled in Phase 2 clinical trial evaluating JZP150 for once-daily treatment of adults with post-traumatic stress disorder
Nov 16, 2021: BetterLife Obtains TD-0148A behavioural pharmacology data confirming its projected non-hallucinogenic property
Nov 09, 2021: Tonix Pharmaceuticals presents Phase 1 formulation development data for TNX-601 CR in a poster presentation at CNS Summit 2021
Nov 08, 2021: Halucenex receives positive USP 61 and USP 62 results
Nov 03, 2021: COMPASS Pathways to launch phase II trial of COMP360 psilocybin therapy for post-traumatic stress disorder
Sep 27, 2021: BetterLife files patent for TD-0148A for treatment of cluster headaches and related disorders
Sep 23, 2021: Wake Network receives certificate of drug registration for microdose formulation in Jamaica
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Companies, 2022 (Contd..1)
Number of Products under Development by Companies, 2022 (Contd..2)
Number of Products under Development by Companies, 2022 (Contd..3)
Number of Products under Development by Universities/Institutes, 2022
Products under Development by Companies, 2022
Products under Development by Companies, 2022 (Contd..1)
Products under Development by Companies, 2022 (Contd..2)
Products under Development by Companies, 2022 (Contd..3)
Products under Development by Companies, 2022 (Contd..4)
Products under Development by Universities/Institutes, 2022
Number of Products by Stage and Target, 2022
Number of Products by Stage and Target, 2022 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2022
Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Ache Laboratorios Farmaceuticos SA, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Actinogen Medical Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Addex Therapeutics Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aision Biotechnologies Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Algernon Pharmaceuticals Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Allied Corp, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Alto Neuroscience Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Alzamend Neuro Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Amorsa Therapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Anagin Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Ananda Scientific Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Apex Labs Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Aptinyx Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by ARMGO Pharma Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Artelo Biosciences Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Avicanna Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Better Life Pharmaceuticals Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionomics Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bionorica SE, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by BioXcel Therapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Boehringer Ingelheim International GmbH, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Braxia Scientific Corp, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Bright Minds Biosciences Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Cannabis Science Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Chronos Therapeutics Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Compass Pathways Plc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Corcept Therapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Delix Therapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Eli Lilly and Co, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Embera NeuroTherapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by EmpathBio, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Endosane Pharmaceuticals GmbH, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Enveric Biosciences Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by EpiVario Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Evecxia Therapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Exxel Pharma Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by H. Lundbeck AS, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Halucenex Life Sciences Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Immodulon Therapeutics Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by INVENT Pharmaceuticals Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by iX Biopharma Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Jazz Pharmaceuticals Plc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Johnson & Johnson, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Kdac Therapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lactocore Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lennham Pharmaceuticals Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Lixte Biotechnology Holdings Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Mindstate Design Labs, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Mydecine Innovations Group Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Nanomerics Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neuritek Therapeutics Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroNascent Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NeuroPharm Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Neurovation Labs Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by NRX Pharmaceuticals Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Omeros Corp, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by One World Cannabis Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Otsuka Pharmaceutical Co Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by PharmaTher Holdings Ltd, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Praxis Precision Medicines Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Protagenic Therapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Psy Therapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by PsyBio Therapeutics Corp, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sage Therapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Sanofi, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Scientus Pharma Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Seelos Therapeutics, Inc., 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Synendos Therapeutics AG, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Tonix Pharmaceuticals Holding Corp, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Virpax Pharmaceuticals Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by VistaGen Therapeutics Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Pipeline by Wake Network Inc, 2022
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, 2022
Post-Traumatic Stress Disorder (PTSD) - Dormant Projects, 2022 (Contd..1)
Post-Traumatic Stress Disorder (PTSD) - Discontinued Products, 2022
List of Figures
Number of Products under Development for Post-Traumatic Stress Disorder (PTSD), 2022
Number of Products under Development by Companies, 2022
Number of Products under Development by Universities/Institutes, 2022
Number of Products by Top 10 Targets, 2022
Number of Products by Stage and Top 10 Targets, 2022
Number of Products by Top 10 Mechanism of Actions, 2022
Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022
